Hematocrit >= 25% (may be reached by transfusion)
Hematocrit > 30%
Hematocrit <30 percent or Hemoglobin < 10 g/dL
Hematocrit >= 27%
Hematocrit >= 28% obtained < 4 weeks prior to starting treatment
Hematocrit (Hct) >= 28% within 30 days of enrollment to study
Hematocrit < 27%
Hematocrit < 30%
Documented adequate hematocrit > 35% for males and 33% for females
DONOR: Has not developed a new malignancy requiring chemotherapy or radiation in the interval since apheresis for initial hematocrit (HCT)
Hematocrit >= 30%
Hematocrit >= 27.0%
Adequate hematocrit independent of red cell transfusions
Hematocrit >= 30 performed within 60 days of enrollment
Hematocrit (Hct) less than or equal to 24%
Hematocrit >= 28%
Hematocrit > 25%
Hematocrit ?30%
Hematocrit >= 30%
Hematocrit of greater than 30%
DONOR: Hematocrit > 35%
Hematocrit >= 30%
Hematocrit < 30%
Hematocrit >= 29%
Hematocrit >= 30%
DONOR: Hematocrit > 35% for males and 33% for females
DONOR: hemoglobin/hematocrit; 12.5-18 g/dl, 38 to 54%
Hematocrit >= 30%, may be reached by transfusion
Hematocrit >= 27.0%
Hematocrit (HCT) >= 30%
Hematocrit ? 25% or hemoglobin ?9 g/100 mL
Hematocrit > 25%
Hematocrit at screening and at initiation of idasanutlin > 40%
Hematocrit > 29% within 14 days prior to treatment initiation
Hematocrit > 21%
Hematocrit (HCT) >= 30%
Hematocrit > 50%
Hematocrit >= 29%
Hematocrit > 29%
Significant anemia with hemoglobin level less than 7 g/dL or a hematocrit less than 21%
Anemia (hematocrit < 28%)
Anemia (hematocrit < 28%)
Hematocrit >= the lower institutional limit
Hematocrit >= 29%
Hemoglobin >= 10 g/dL or hematocrit >= 30%
Hemoglobin >= 10 g/dL or hematocrit >= 30% obtained =< 45 days prior to randomization
Hematocrit within normal institutional limits
Unacceptable hemogram: hematocrit < 34%
Hematocrit < 22%
Hematocrit < 22%
Hematocrit > 25%
